Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL4I1 | Q96RQ9 | 6/20 | 0.58 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.47 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30947995 | 0.88 | IL4I1 (0.71) | IL4I1HCRTR1HCRTR2RXFP1TP53 | |
| SCHEMBL30948113 | 0.87 | IL4I1 (0.60) | IL4I1RXFP1POLBTP53LMNA | |
| SCHEMBL30947925 | 0.81 | IL4I1 (0.47) | IL4I1RXFP1POLBTP53LMNA | |
| SCHEMBL27163306 | 0.81 | IL4I1 (0.77) | IL4I1RXFP1POLBTP53LMNA | |
| SCHEMBL30948009 | 0.81 | IL4I1 (0.59) | IL4I1RXFP1POLBTP53 | |
| SCHEMBL30948019 | 0.81 | IL4I1 (0.55) | IL4I1RXFP1CYP11B1POLBTP53 | |
| SCHEMBL30948258 | 0.79 | IL4I1 (0.74) | IL4I1RXFP1POLBTP53LMNA | |
| SCHEMBL27163079 | 0.79 | IL4I1 (0.74) | IL4I1RXFP1POLBTP53LMNA | |
| SCHEMBL27163500 | 0.78 | IL4I1 (0.58) | IL4I1RXFP1CYP11B1POLBTP53 | |
| SCHEMBL30948254 | 0.77 | IL4I1 (0.56) | IL4I1RXFP1POLBTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246937-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2024-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246937-A1 | IL4I1 INHIBITORS AND METHODS OF USE | IL4I1, IL4, IL2 | IL4I1 1/4885HCRTR1 3838/4885HCRTR2 4549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.